Sort   by:  
 Page size 
Increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost androgen receptor (AR) signaling. AVPC tumors may also...
ORGANISM(S): Homo sapiens (Human) 
2020-05-29 | PXD012970 | Pride
Increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost androgen receptor (AR) signaling. AVPC tumors may also...
ORGANISM(S): Homo sapiens (Human) 
2020-05-29 | PXD012971 | Pride
Sort   by:  
 Page size